MICU2

Across TCGA pan-cancer cohorts, MICU2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MICU2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where MICU2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MICU2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

PDAC, LUAD, and COAD are the cancer types where MICU2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MICU2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+0.896	<.001	9	view →
LUAD	Female	II,III,IV	+0.488	<.001	9	view →
COAD	All	II,III,IV	+0.118	<.001	4	view →
OV	All	All	+0.398	.003	2	view →
CCRCC	Male	III,IV	+0.188	.015	1	view →
LSCC	All	II,III,IV	−0.084	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MICU2–PDAC

Open the PDAC breakdown →